- Home
- LXRX vs CRVS Comparison
LXRX vs CRVS Comparison
Compare LXRX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- CRVS
- Stock Information
- Founded
- LXRX 1995
- CRVS 2014
- Country
- LXRX United States
- CRVS United States
- Employees
- LXRX N/A
- CRVS N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- CRVS Health Care
- Exchange
- LXRX Nasdaq
- CRVS Nasdaq
- Market Cap
- LXRX 552.4M
- CRVS 459.0M
- IPO Year
- LXRX 2000
- CRVS 2016
- Fundamental
- Price
- LXRX $1.37
- CRVS $7.59
- Analyst Decision
- LXRX Buy
- CRVS Strong Buy
- Analyst Count
- LXRX 5
- CRVS 4
- Target Price
- LXRX $3.23
- CRVS $13.75
- AVG Volume (30 Days)
- LXRX 2.6M
- CRVS 1.0M
- Earning Date
- LXRX 11-04-2025
- CRVS 11-04-2025
- Dividend Yield
- LXRX N/A
- CRVS N/A
- EPS Growth
- LXRX N/A
- CRVS N/A
- EPS
- LXRX N/A
- CRVS N/A
- Revenue
- LXRX $58,432,000.00
- CRVS N/A
- Revenue This Year
- LXRX $66.55
- CRVS N/A
- Revenue Next Year
- LXRX N/A
- CRVS N/A
- P/E Ratio
- LXRX N/A
- CRVS N/A
- Revenue Growth
- LXRX 1504.83
- CRVS N/A
- 52 Week Low
- LXRX $0.28
- CRVS $2.54
- 52 Week High
- LXRX $2.08
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- LXRX 48.43
- CRVS 58.78
- Support Level
- LXRX $1.36
- CRVS $6.81
- Resistance Level
- LXRX $1.48
- CRVS $7.96
- Average True Range (ATR)
- LXRX 0.10
- CRVS 0.52
- MACD
- LXRX -0.02
- CRVS -0.03
- Stochastic Oscillator
- LXRX 3.33
- CRVS 67.50
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).